PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
25981734-8	2015	Of the four tested PARP-1 inhibitors only AZD2461 strongly affected cell cycle progression.	AZD2461	42-49	poly(ADP-ribose) polymerase 1	Homo sapiens	19-25
27550455-0	2016	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.	AZD2461	19-26	poly (ADP-ribose) polymerase family, member 1	Mus musculus	4-8
27550455-0	2016	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.	AZD2461	19-26	poly (ADP-ribose) polymerase family, member 3	Mus musculus	62-67
27550455-1	2016	The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy.	AZD2461	19-26	poly (ADP-ribose) polymerase family, member 1	Mus musculus	4-8
27550455-1	2016	The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy.	AZD2461	19-26	poly (ADP-ribose) polymerase family, member 1	Mus musculus	98-102
26100884-6	2015	Indeed, resistance could be circumvented by using another PARP inhibitor, AZD2461, which is a poor Pgp substrate.	AZD2461	74-81	poly (ADP-ribose) polymerase family, member 1	Mus musculus	58-62
26100884-6	2015	Indeed, resistance could be circumvented by using another PARP inhibitor, AZD2461, which is a poor Pgp substrate.	AZD2461	74-81	phosphoglycolate phosphatase	Mus musculus	99-102
23103855-5	2013	Importantly, PARPi resistance was minimized by long-term treatment with the novel PARP inhibitor AZD2461, which is a poor P-glycoprotein substrate.	AZD2461	97-104	poly (ADP-ribose) polymerase family, member 1	Mus musculus	13-17
25337581-7	2014	RESULTS: Unlike NU1025, AZD2461, a new PARP-1 inhibitor, markedly reduced the numbers of living MCF-7 and SKBr-3 cells.	AZD2461	24-31	poly(ADP-ribose) polymerase 1	Homo sapiens	39-45
25337581-10	2014	CONCLUSIONS: Our data show that inhibition of PARP-1 by AZD2461 is synthetically lethal for NU1025-resistant MCF-7 and SKBr-3 breast cancer cells.	AZD2461	56-63	poly(ADP-ribose) polymerase 1	Homo sapiens	46-52
34653407-0	2021	Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53.	AZD2461	21-28	poly(ADP-ribose) polymerase 1	Homo sapiens	29-33
34728235-2	2022	Here we show that the PARP-1/2/3 inhibitor AZD2461 in combination with the CHK1 inhibitor UCN-01 altered the DNA damage response and reduced cell proliferation in PEL cells, an aggressive B cell lymphoma highly resistant to chemotherapies.	AZD2461	43-50	poly(ADP-ribose) polymerase 1	Homo sapiens	22-32
34728235-3	2022	AZD2461/UCN-01 combination activated p53/p21 and downregulated c-Myc in these cells, leading to a reduced expression level of RAD51, molecule involved in DNA repair.	AZD2461	0-7	tumor protein p53	Homo sapiens	37-40
34728235-3	2022	AZD2461/UCN-01 combination activated p53/p21 and downregulated c-Myc in these cells, leading to a reduced expression level of RAD51, molecule involved in DNA repair.	AZD2461	0-7	H3 histone pseudogene 16	Homo sapiens	41-44
34728235-3	2022	AZD2461/UCN-01 combination activated p53/p21 and downregulated c-Myc in these cells, leading to a reduced expression level of RAD51, molecule involved in DNA repair.	AZD2461	0-7	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	63-68
34728235-3	2022	AZD2461/UCN-01 combination activated p53/p21 and downregulated c-Myc in these cells, leading to a reduced expression level of RAD51, molecule involved in DNA repair.	AZD2461	0-7	RAD51 recombinase	Homo sapiens	126-131
34728235-4	2022	The effect of AZD2461/UCN-01 on c-Myc and p53/p21 was inter-dependent and, besides impairing cell proliferation, contributed to the activation of the replicative cycle of KSHV, carried in a latent state in PEL cells.	AZD2461	14-21	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	32-37
34728235-4	2022	The effect of AZD2461/UCN-01 on c-Myc and p53/p21 was inter-dependent and, besides impairing cell proliferation, contributed to the activation of the replicative cycle of KSHV, carried in a latent state in PEL cells.	AZD2461	14-21	tumor protein p53	Homo sapiens	42-45
34728235-4	2022	The effect of AZD2461/UCN-01 on c-Myc and p53/p21 was inter-dependent and, besides impairing cell proliferation, contributed to the activation of the replicative cycle of KSHV, carried in a latent state in PEL cells.	AZD2461	14-21	H3 histone pseudogene 16	Homo sapiens	46-49
34653407-0	2021	Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53.	AZD2461	21-28	tumor protein p53	Homo sapiens	100-103
34653407-5	2021	In this study, we addressed this topic by using a well-tolerated PARP 1/2/3 inhibitor, namely AZD2461, against colon cancer cell lines with different p53 status.	AZD2461	94-101	poly(ADP-ribose) polymerase 1	Homo sapiens	65-75
34653407-6	2021	We found that AZD2461 reduced cell proliferation in wtp53 and p53-/- cancer cells by increasing ROS and DNA damage, while R273H mutant (mut) p53 counteracted these effects.	AZD2461	14-21	tumor protein p53	Homo sapiens	62-65
34653407-7	2021	Moreover, AZD2461 improved the reduction of cell proliferation by low dose radiation (IR) in wtp53 cancer cells, in which a down-regulation of BRCA-1 occurred.	AZD2461	10-17	BRCA1 DNA repair associated	Homo sapiens	143-149
34653407-8	2021	AZD2461 did not affect cell proliferation of mutp53 colon cancer cells also in combination with low dose radiation, suggesting that only wt p53 or p53 null colon cancer cells could benefit AZD2461 treatment.	AZD2461	189-196	tumor protein p53	Homo sapiens	140-143
34653407-8	2021	AZD2461 did not affect cell proliferation of mutp53 colon cancer cells also in combination with low dose radiation, suggesting that only wt p53 or p53 null colon cancer cells could benefit AZD2461 treatment.	AZD2461	189-196	tumor protein p53	Homo sapiens	147-150
32342268-0	2020	[18F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging.	AZD2461	5-12	poly (ADP-ribose) polymerase family, member 1	Mus musculus	42-46
35526484-4	2022	Indeed, PARP and CHK1 inhibition by AZD2461 and UCN-01, by downregulating c-Myc, reduced the expression of XBP1s, constitutively expressed in these cells, and upregulated CHOP.	AZD2461	36-43	collagen type XI alpha 2 chain	Homo sapiens	8-12
35526484-4	2022	Indeed, PARP and CHK1 inhibition by AZD2461 and UCN-01, by downregulating c-Myc, reduced the expression of XBP1s, constitutively expressed in these cells, and upregulated CHOP.	AZD2461	36-43	checkpoint kinase 1	Homo sapiens	17-21
35526484-4	2022	Indeed, PARP and CHK1 inhibition by AZD2461 and UCN-01, by downregulating c-Myc, reduced the expression of XBP1s, constitutively expressed in these cells, and upregulated CHOP.	AZD2461	36-43	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	74-79
35526484-4	2022	Indeed, PARP and CHK1 inhibition by AZD2461 and UCN-01, by downregulating c-Myc, reduced the expression of XBP1s, constitutively expressed in these cells, and upregulated CHOP.	AZD2461	36-43	DNA damage inducible transcript 3	Homo sapiens	171-175
35216385-3	2022	In this study, we found that TSA and, even more effectively, VPA synergized with AZD2461, PARP1, 2 and 3 inhibitor (PARPi) to induce DNA damage and reduce pancreatic cancer cell survival.	AZD2461	81-88	poly(ADP-ribose) polymerase 1	Homo sapiens	90-104
32342268-3	2020	Herein, we propose to study AZD2461, a PARP inhibitor with lower affinity towards PARP3, and to investigate its potential for PARP targeting in vivo.	AZD2461	28-35	poly (ADP-ribose) polymerase family, member 1	Mus musculus	39-43
32342268-3	2020	Herein, we propose to study AZD2461, a PARP inhibitor with lower affinity towards PARP3, and to investigate its potential for PARP targeting in vivo.	AZD2461	28-35	poly (ADP-ribose) polymerase family, member 3	Mus musculus	82-87
32342268-3	2020	Herein, we propose to study AZD2461, a PARP inhibitor with lower affinity towards PARP3, and to investigate its potential for PARP targeting in vivo.	AZD2461	28-35	poly (ADP-ribose) polymerase family, member 1	Mus musculus	82-86
32342268-4	2020	METHODS: Using the Cu-mediated 18F-fluorodeboronation of a carefully designed radiolabelling precursor, we accessed the 18F-labelled isotopologue of the PARP inhibitor AZD2461.	AZD2461	168-175	poly (ADP-ribose) polymerase family, member 1	Mus musculus	153-157
32342268-8	2020	[18F]AZD2461 was taken up in vivo in PARP1-expressing tumours, and the highest uptake was observed for PSN-1 cells (7.34 +- 1.16 %ID/g).	AZD2461	5-12	poly (ADP-ribose) polymerase family, member 1	Mus musculus	37-42
32342268-8	2020	[18F]AZD2461 was taken up in vivo in PARP1-expressing tumours, and the highest uptake was observed for PSN-1 cells (7.34 +- 1.16 %ID/g).	AZD2461	5-12	5'-nucleotidase, cytosolic III	Mus musculus	103-108
31102368-0	2019	Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells Background: Prostate cancer (Pca) is a heterogeneous disease, and current treatments are not based on molecular stratification.	AZD2461	70-77	poly(ADP-ribose) polymerase 1	Homo sapiens	53-57
31102368-0	2019	Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells Background: Prostate cancer (Pca) is a heterogeneous disease, and current treatments are not based on molecular stratification.	AZD2461	70-77	vascular endothelial growth factor A	Homo sapiens	94-98
31102368-2	2019	Therefore, this preliminary study was designed to evaluate whether PTEN expression status could have an impact on the sensitivity of invasive Pca cells to the PARP inhibitor, AZD2461.	AZD2461	175-182	phosphatase and tensin homolog	Homo sapiens	67-71
31102368-2	2019	Therefore, this preliminary study was designed to evaluate whether PTEN expression status could have an impact on the sensitivity of invasive Pca cells to the PARP inhibitor, AZD2461.	AZD2461	175-182	poly(ADP-ribose) polymerase 1	Homo sapiens	159-163
31102368-7	2019	Treatment of cells by AZD2461 also caused a significant increase in apoptosis through caspase3 activation in both cell lines.	AZD2461	22-29	caspase 3	Homo sapiens	86-94
31102368-9	2019	Conclusion: AZD2461 suppresses the growth of prostate tumor cells since AZD2461 monotherapy could prove to be efficacious, especially against cells not expressing PTEN besides activating the possible apoptosis-independent cell death pathways.	AZD2461	12-19	phosphatase and tensin homolog	Homo sapiens	163-167
30390553-0	2019	Synthesis and evaluation of an AZD2461 [18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant.	AZD2461	31-38	poly(ADP-ribose) polymerase 1	Homo sapiens	88-94
31423128-2	2019	This study was designed to determine the efficacy of combination therapy of a histone deacetylase inhibitor, valproic acid (VPA) and a novel PARP inhibitor AZD2461 in both PC-3 (PTEN-mutated) and DU145 (PTEN-unmutated) prostate cancer cell lines.	AZD2461	156-163	collagen type XI alpha 2 chain	Homo sapiens	141-145
31423128-2	2019	This study was designed to determine the efficacy of combination therapy of a histone deacetylase inhibitor, valproic acid (VPA) and a novel PARP inhibitor AZD2461 in both PC-3 (PTEN-mutated) and DU145 (PTEN-unmutated) prostate cancer cell lines.	AZD2461	156-163	proprotein convertase subtilisin/kexin type 1	Homo sapiens	172-176
31423128-2	2019	This study was designed to determine the efficacy of combination therapy of a histone deacetylase inhibitor, valproic acid (VPA) and a novel PARP inhibitor AZD2461 in both PC-3 (PTEN-mutated) and DU145 (PTEN-unmutated) prostate cancer cell lines.	AZD2461	156-163	phosphatase and tensin homolog	Homo sapiens	178-182
31423128-7	2019	We observed a synergistic relationship between VPA and AZD2461 in all affected fractions of PC-3 cells (CI<0.9), but not in DU145 cells (CI>1.1).	AZD2461	55-62	proprotein convertase subtilisin/kexin type 1	Homo sapiens	92-96
31423128-8	2019	Annexin-V staining analysis revealed a significant induction of apoptosis when PC-3 cells were treated with VPA+AZD2461 (p<0.05).	AZD2461	112-119	annexin A5	Homo sapiens	0-9
31423128-8	2019	Annexin-V staining analysis revealed a significant induction of apoptosis when PC-3 cells were treated with VPA+AZD2461 (p<0.05).	AZD2461	112-119	proprotein convertase subtilisin/kexin type 1	Homo sapiens	79-83
31423128-9	2019	Both mRNA and protein levels of Rad51 and Mre11 were significantly decreased in PC-3 cells co-treated with VPA+AZD2461 while enhanced H2AX phosphorylation was found in PC-3 cells after 12 and 24 hours of co-treatment (p<0.05).	AZD2461	111-118	RAD51 recombinase	Homo sapiens	32-37
31423128-9	2019	Both mRNA and protein levels of Rad51 and Mre11 were significantly decreased in PC-3 cells co-treated with VPA+AZD2461 while enhanced H2AX phosphorylation was found in PC-3 cells after 12 and 24 hours of co-treatment (p<0.05).	AZD2461	111-118	MRE11 homolog, double strand break repair nuclease	Homo sapiens	42-47
31423128-9	2019	Both mRNA and protein levels of Rad51 and Mre11 were significantly decreased in PC-3 cells co-treated with VPA+AZD2461 while enhanced H2AX phosphorylation was found in PC-3 cells after 12 and 24 hours of co-treatment (p<0.05).	AZD2461	111-118	proprotein convertase subtilisin/kexin type 1	Homo sapiens	80-84
31423128-10	2019	Our findings established a preclinical rationale for selective targeting of HR repair pathways by a combination of VPA and AZD2461 as a mechanism for reducing the HR pathway sufficiency in PTEN-mutated prostate cancer cells.	AZD2461	123-130	phosphatase and tensin homolog	Homo sapiens	189-193
31380319-3	2019	This study wishes to assess whether the combination of AZD2461 as a newly developed PARP1 inhibitor and valproic acid (VPA), a histone deacetylase inhibitor could effectively reduce the growth of MCF-7 cells with no fundamental DNA repair defect.	AZD2461	55-62	poly(ADP-ribose) polymerase 1	Homo sapiens	84-89
30390553-1	2019	Poly(ADP-ribose)polymerase-1 inhibitor (PARPi) AZD2461 was designed to be a weak P-glycoprotein (P-gp) analogue of FDA approved olaparib.	AZD2461	47-54	poly(ADP-ribose) polymerase 1	Homo sapiens	0-28
30390553-1	2019	Poly(ADP-ribose)polymerase-1 inhibitor (PARPi) AZD2461 was designed to be a weak P-glycoprotein (P-gp) analogue of FDA approved olaparib.	AZD2461	47-54	ATP binding cassette subfamily B member 1	Homo sapiens	81-95
30390553-1	2019	Poly(ADP-ribose)polymerase-1 inhibitor (PARPi) AZD2461 was designed to be a weak P-glycoprotein (P-gp) analogue of FDA approved olaparib.	AZD2461	47-54	ATP binding cassette subfamily B member 1	Homo sapiens	97-101
30390553-2	2019	With this chemical property in mind, we utilized the AZD2461 ligand architecture to develop a CNS penetrant and PARP-1 selective imaging probe, in order to investigate PARP-1 mediated neuroinflammation and neurodegenerative diseases, such as Alzheimer"s and Parkinson"s.	AZD2461	53-60	poly(ADP-ribose) polymerase 1	Homo sapiens	112-118
30390553-2	2019	With this chemical property in mind, we utilized the AZD2461 ligand architecture to develop a CNS penetrant and PARP-1 selective imaging probe, in order to investigate PARP-1 mediated neuroinflammation and neurodegenerative diseases, such as Alzheimer"s and Parkinson"s.	AZD2461	53-60	poly(ADP-ribose) polymerase 1	Homo sapiens	168-174
30390553-3	2019	Our work led to the identification of several high-affinity PARPi, including AZD2461 congener 9e (PARP-1 IC50 = 3.9 +- 1.2 nM), which was further evaluated as a potential 18F-PET brain imaging probe.	AZD2461	77-84	poly(ADP-ribose) polymerase 1	Homo sapiens	98-104
30357520-7	2019	RESULTS: Olaparib and AZD2461 dose-dependently reduced growth of both RH30 and RD cells by arresting growth at G2/M phase and by modulating the expression, activation and subcellular localization of specific cell cycle regulators.	AZD2461	22-29	Rh blood group D antigen	Homo sapiens	70-74
30357520-8	2019	Downregulation of phospho-AKT levels and accumulation of gammaH2AX, a specific marker of DNA damage, were significantly and persistently induced by Olaparib and AZD2461 exposure, this leading to apoptosis-related cell death.	AZD2461	161-168	AKT serine/threonine kinase 1	Homo sapiens	26-29
30252484-0	2018	ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.	AZD2461	61-68	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	0-5
30252484-0	2018	ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.	AZD2461	61-68	poly (ADP-ribose) polymerase family, member 1	Mus musculus	46-50
30252484-4	2018	AZD2461 is a novel PARP inhibitor that is unaffected by P-gp mediated resistance in breast cancer models and thus appears to have promising characteristics for brain penetration.	AZD2461	0-7	poly (ADP-ribose) polymerase family, member 1	Mus musculus	19-23
30198004-0	2018	Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions.	AZD2461	34-41	ATP binding cassette subfamily B member 1	Homo sapiens	120-134
30198004-2	2018	AZD2461, a congener of FDA approved olaparib, is a potent PARPi with high affinity for PARP-1 and nonsubstrate for P-glycoprotein (P-gp), an attractive characteristic for cancer therapeutics.	AZD2461	0-7	poly(ADP-ribose) polymerase 1	Homo sapiens	87-93
30198004-2	2018	AZD2461, a congener of FDA approved olaparib, is a potent PARPi with high affinity for PARP-1 and nonsubstrate for P-glycoprotein (P-gp), an attractive characteristic for cancer therapeutics.	AZD2461	0-7	ATP binding cassette subfamily B member 1	Homo sapiens	115-129
30198004-2	2018	AZD2461, a congener of FDA approved olaparib, is a potent PARPi with high affinity for PARP-1 and nonsubstrate for P-glycoprotein (P-gp), an attractive characteristic for cancer therapeutics.	AZD2461	0-7	ATP binding cassette subfamily B member 1	Homo sapiens	131-135
30198004-3	2018	Analogues of AZD2461 were synthesized and profiled in BRCA1 functional and nonfunctional cell lines, revealing compounds (2, 3, and 5) of low cytotoxicity and excellent PARP-1 affinities (~4-8 nM).	AZD2461	13-20	BRCA1 DNA repair associated	Homo sapiens	54-59
30198004-3	2018	Analogues of AZD2461 were synthesized and profiled in BRCA1 functional and nonfunctional cell lines, revealing compounds (2, 3, and 5) of low cytotoxicity and excellent PARP-1 affinities (~4-8 nM).	AZD2461	13-20	poly(ADP-ribose) polymerase 1	Homo sapiens	169-175